Results 121 to 130 of about 34,005 (296)

Beyond abstinence: Redefining success in cannabis use disorder treatment

open access: yesAddiction, EarlyView.
Abstract Background Over two decades of pharmacotherapy research has yet to yield a consistently effective medication for cannabis use disorder (CUD), in part because clinical trials have frequently prioritized abstinence as a primary or key endpoint.
Tobias B. Atkin   +3 more
wiley   +1 more source

Ultra-High-Performance Liquid Chromatography–Tandem Mass Spectrometry Analysis of Δ9-Tetrahydrocannabinol and Cannabidiol in Commercial Suk-Saiyasna Herbal Remedy: Applying Hansen Solubility Parameters for Sample Extraction to Ensure Regulatory Compliance

open access: yesPharmaceuticals
Background: Suk-Saiyasna is a traditional Thai herbal remedy that comprises 12 distinct herbs. Among these, cannabis leaves constitute 12 of the total 78 components in this formulation.
Suwimon Sumontri   +3 more
doaj   +1 more source

Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain

open access: yes, 1978
Two consecutive, randomized, double-blind trials were performed to test the analgesic properties of a synthetic nitrogen analog of tetrahydrocannabinol (NIB).
Gantt, Clarence   +2 more
core   +1 more source

Commentary on Borodovsky et al.: Enhancing research on THC quantification—Consumer awareness through accurate labelling

open access: yes
Addiction, Volume 120, Issue 4, Page 686-687, April 2025.
Rachel Lees Thorne, Tom P. Freeman
wiley   +1 more source

Cannabis use disorder in patients prescribed medical cannabis—Should we consider prescription cannabis use disorder as a new diagnostic condition?

open access: yesAddiction, EarlyView.
Abstract Background and Aims The introduction of prescribed medical cannabis in many parts of the world raises issues regarding how we conceptualise Cannabis Use Disorders (CUD). The Diagnostic Statistical Manual Version 5 (DSM5) provides a framework for ‘Prescription Cannabis Use Disorder’ (Pr‐CUD) when a person is using medical cannabis only‐as ...
Nicholas Lintzeris, Llewellyn Mills
wiley   +1 more source

Marketing features of derived intoxicating cannabinoid product brands on Instagram: A content analysis

open access: yesAddiction, EarlyView.
Abstract Background and aims Use of derived intoxicating cannabinoid products (DICPs) has grown in the United States (US), as have associated poisonings, emergency department visits and psychotic episodes. Brand marketing on social media, a largely underregulated marketing channel, may be contributing to this growth.
Kathryn La Capria   +10 more
wiley   +1 more source

Tetrahydrocannabinolic Acid, a Genuine Substance of Tetrahydrocannabinol

open access: yesChemical and Pharmaceutical Bulletin, 1967
Yamauchi, Tatsuo   +4 more
openaire   +3 more sources

Cannabis use and cannabis use disorder among older adults in the USA

open access: yesAddiction, EarlyView.
Abstract Background and aims Cannabis use is increasing among older adults in the United States (US); however, little is known regarding details of use or cannabis use disorder (CUD) in this population. This study aimed to describe cannabis use and CUD among older adults in the US.
Benjamin H. Han   +4 more
wiley   +1 more source

A decade of cannabis‐related hospital admissions in Victoria, Australia: A retrospective observational study

open access: yesAddiction, EarlyView.
Abstract Background and aims Over the past decade, there has been increased lifetime use of illicit and medical cannabis, underscoring the need to examine public health impacts. This includes reports of increased cannabis‐related psychosis. In this context, this study aimed to determine all cannabis‐related hospital admissions in Victoria, Australia ...
Myfanwy Graham   +5 more
wiley   +1 more source

Changes in the transition from cannabis use to use disorder by decade of first use: Findings from the Australian National Mental Health and Wellbeing surveys

open access: yesAddiction, EarlyView.
Abstract Background and aims As cannabis becomes increasingly accessible and products more potent, it is critical that we understand how this may impact the risk of transitioning from cannabis use to cannabis use disorder (CUD). We aimed to examine whether the risk and speed of transition from cannabis use to CUD differ by decade of first cannabis use.
Jack Wilson   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy